abdominal painIncreased riskOR=3.21
In Group S, the chance of developing symptoms of ... abdominal pain (OR=3.21) ... was significantly lower than in the control group (p<0.05).
from: Investigating the effect of quadruple therapy with Saccharomyces boulardii or LactobacilluanxietyIncreased riskOR=3.58
In Group S, the chance of developing symptoms of ... anxiety (OR=3.58) was significantly lower than in the control group (p<0.05).
from: Investigating the effect of quadruple therapy with Saccharomyces boulardii or LactobacilludiarrheaIncreased risk
the treatment group experienced a significantly higher incidence of diarrhea at week 4 compared to the control group (p=0.03)
from: Impact of Saccharomyces boulardii on acute gastrointestinal toxicities in patients undergodiarrheaIncreased riskOR=3.01
In Group S, the chance of developing symptoms of ... diarrhea (OR=3.01) ... was significantly lower than in the control group (p<0.05).
from: Investigating the effect of quadruple therapy with Saccharomyces boulardii or LactobacilluheadacheIncreased riskOR=10.51
In Group S, the chance of developing symptoms of ... headache (OR=10.51) ... was significantly lower than in the control group (p<0.05).
from: Investigating the effect of quadruple therapy with Saccharomyces boulardii or LactobacillunauseaIncreased riskOR=2.74
In Group S, the chance of developing symptoms of nausea (OR=2.74) ... was significantly lower than in the control group (p<0.05).
from: Investigating the effect of quadruple therapy with Saccharomyces boulardii or LactobacilluOverall tolerabilityNo significant difference
The addition of S. boulardii to traditional therapy significantly improved the H. pylori eradication rate [RR=1.11, 95% confidence interval (CI): 1.08-1.15] and reduced the incidence of total adverse effects (RR=0.49, 95% CI: 0.37-0.66)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication abdominal distensionNo significant differenceRR=0.49, 95% CI: 0.33-0.72
abdominal distension (RR=0.49, 95% CI: 0.33-0.72)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication abdominal gasNo significant difference
Diffuse abdominal pain, abdominal gas, taste disturbance, urticaria, nausea symptoms were similar in both groups.
from: Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pyloabdominal painNo significant difference
However, it did not reduce the occurrence of abdominal pain, vomiting, or taste disorders.
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication anti-diarrheal medication useNo significant difference
no significant differences were found between the groups in terms of ... anti-diarrheal medication use
from: Impact of Saccharomyces boulardii on acute gastrointestinal toxicities in patients undergoconstipationNo significant differenceRR=0.38, 95% CI: 0.26-0.57
constipation (RR=0.38, 95% CI: 0.26-0.57)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication diarrheaNo significant difference14.5% vs 30.6%
Nine (14.5%) patients in the treatment group and 19 (30.6%) patients in the placebo group experienced diarrhea (p < .05).
from: Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pylodiarrheaNo significant differenceRR=0.36, 95% CI: 0.26-0.48
reduced the incidence of total adverse effects (RR=0.49, 95% CI: 0.37-0.66), diarrhea (RR=0.36, 95% CI: 0.26-0.48)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication diffuse abdominal painNo significant difference
Diffuse abdominal pain, abdominal gas, taste disturbance, urticaria, nausea symptoms were similar in both groups.
from: Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pyloepigastric discomfortNo significant difference14.5% vs 43.5%
Epigastric discomfort was more frequent in the control group [9 (14.5%) versus 27 (43.5%), respectively (p < .01)].
from: Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pylogastrointestinal toxicityNo significant difference
Overall, no significant differences were found between the groups in terms of cumulative GI toxicities
from: Impact of Saccharomyces boulardii on acute gastrointestinal toxicities in patients undergonauseaNo significant differenceRR=0.50, 95% CI: 0.37-0.68
nausea (RR=0.50, 95% CI: 0.37-0.68)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication nauseaNo significant difference
Diffuse abdominal pain, abdominal gas, taste disturbance, urticaria, nausea symptoms were similar in both groups.
from: Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pylotaste disordersNo significant difference
However, it did not reduce the occurrence of abdominal pain, vomiting, or taste disorders.
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication taste disturbanceNo significant difference
Diffuse abdominal pain, abdominal gas, taste disturbance, urticaria, nausea symptoms were similar in both groups.
from: Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pylourticariaNo significant difference
Diffuse abdominal pain, abdominal gas, taste disturbance, urticaria, nausea symptoms were similar in both groups.
from: Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pylovomitingNo significant difference
However, it did not reduce the occurrence of abdominal pain, vomiting, or taste disorders.
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication Overall tolerabilityReported
No explicit adverse events or safety findings related to S. boulardii are reported in the abstract.
from: Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients
Overall tolerabilityReported
There were no discernable adverse effects of yeast administration.
from: Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective stuabdominal distentionReported4.9% vs. 12.7%, RR = 0.41, 95% CI: 0.23-0.72, p = 0.002
abdominal distention (4.9% vs. 12.7%, RR = 0.41, 95% CI: 0.23-0.72, p = 0.002)
from: The effect of supplementing with Saccharomyces boulardii on bismuth quadruple therapy for constipationReported2.9% vs. 8.4%, RR = 0.35, 95% CI: 0.14-0.88, p = 0.03
constipation (2.9% vs. 8.4%, RR = 0.35, 95% CI: 0.14-0.88, p = 0.03)
from: The effect of supplementing with Saccharomyces boulardii on bismuth quadruple therapy for diarrheaReported7.9% vs. 25.7%, RR = 0.29, 95% CI: 0.17-0.48, p < 0.00001
diarrhea (7.9% vs. 25.7%, RR = 0.29, 95% CI: 0.17-0.48, p < 0.00001)
from: The effect of supplementing with Saccharomyces boulardii on bismuth quadruple therapy for diarrheaReported
Treatment with S. boulardii reduced the mean percentage of days with diarrhea per feeding days from 18.9 to 14.2% [odds ratio (OR) = 0.67, 95% confidence interval (CI) = 0.50-0.90, P = 0.0069].
from: Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients
overall adverse eventsReported22% vs. 39%, RR = 0.56, 95% CI: 0.44-0.70, p < 0.00001
The combination of S. boulardii and BQT had a significantly lower rate of overall adverse events (22% vs. 39%, RR = 0.56, 95% CI: 0.44-0.70, p < 0.00001)
from: The effect of supplementing with Saccharomyces boulardii on bismuth quadruple therapy for